SkinBioTherapeutics PLC - life science company focused on skin health - Notes share price slide but says ‘not aware of any rationale for the movement’.

‘Since our last announcement in May, the team has been extremely busy across all pillars, driving both commercial and development programmes forward. Our partnership with Croda is also moving forward, and it is extremely positive that they wish to explore the additional properties in SkinBiotix,’ Chief Executive Stuart Ashman says.

Current stock price: 11.54 pence, down 12% on Wednesday

12-month change: down 45%

Copyright 2023 Alliance News Ltd. All Rights Reserved.